story protocol couldn't verify baby shark ip was fake before pinkfong token dumped 99%. $ip trades at $2.67b for infrastructure that approved fraudulent ip, deleted evidence, then went silent. korean partnerships worth $100m+ supporting a platform that can't distinguish real from fake intellectual property. ...

Sarah Cork Ph.D. - Patent Attorney Dallas, TX, Sept. 24, 2025 (GLOBE NEWSWIRE) -- PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is pleased to announce that Dr. Sarah Cork is collaborating with the firm as a Senior Patent Attorney. Her arrival underscores PatentVest’s continued growth in the life sciences sector and strengthens its ability to deliver sophisticated intellectual property strategies that drive competitive advantage for clients. Dr. Cork brings more than a decade of experience ...

The World Intellectual Property Office uses 78 indicators to assemble its Global Innovation Index. Here’s how countries ranked in 2025 https://t.co/9znRfBlnlU ...

Core Viewpoint - The company is rebranding as "IP Strategy" to focus on accumulating $IP tokens, the cryptocurrency of the Story Network, and will change its Nasdaq ticker symbol from "CASK" to "IPST" effective September 22, 2025 [1][5]. Group 1: Rebranding and Strategic Shift - The rebranding reflects the company's evolution into a public-market vehicle centered on the $80 trillion intellectual property economy, particularly in artificial intelligence [1][9]. - IP Strategy is the first Nasdaq-listed company to adopt a treasury reserve strategy focused on $IP tokens, aiming to connect public market investors with this emerging asset class [1][9]. Group 2: Shareholder Approval and Financing - At a special meeting on September 18, 2025, shareholders approved all proposals related to a private placement financing transaction, indicating strong confidence in the company's vision [2][3]. - Key measures approved include a potential reverse stock split and an increase in authorized shares from 495 million to 995 million, providing flexibility for growth initiatives and compliance with Nasdaq requirements [2][3]. Group 3: Financial Highlights - The recent private placement financing raised $223.8 million, which included $95 million in cash and $128.8 million in $IP tokens, while eliminating $19.3 million in debt [4][5]. - The company now holds over 53.2 million $IP tokens valued at approximately $731 million based on a closing price of $13.72 as of September 21, 2025 [4][5]. Group 4: Market Position and Future Outlook - With a debt-free balance sheet and substantial $IP treasury, the company is positioned at the intersection of AI, blockchain, and intellectual property, offering a regulated equity-based gateway for investors [7][9]. - The company plans to provide further details on yield-generating mechanisms and has launched a new website featuring a real-time Treasury Dashboard for investors [6][8].

Intellectual property portfolio now includes 228 Patents and 153 Trademarks providing robust protection for the Company's product platforms in the rapidly growing multi-billion dollar veterinary diagnostics market ANN ARBOR, MI / ACCESS Newswire / September 18, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the issuance of four additional ...

中国商务部新闻发言人何亚东：关于Tiktok问题，中方立场是一贯的，我们反对将科技和经贸问题政治化、工具化、武器化，绝不会以牺牲原则立场、企业利益和国际公平正义为代价，寻求达成任何协议。同时，中国政府充分尊重企业意愿，支持企业在符合市场原则基础上开展平等商业谈判。中国政府将依法审批Tiktok所涉及的技术出口、知识产权、使用权授权等事宜，也希望美方能够按照双方达成的共识，为包括Tiktok在内的中国企业在美持续运营提供开放、公平、公正和非歧视的营商环境，推动中美经贸关系稳定、健康、可持续发展。外汇交易员 (@myfxtrader):中国国家互联网信息办公室副主任王京涛指出，中美双方在充分尊重企业意愿和市场规律的基础上，就通过TikTok美国用户数据和内容安全业务委托运营、算法等知识产权使用权授权等方式解决TikTok问题，达成了基本共识。中国政府将依法审批TikTok所涉及的技术出口、知识产权使用权授权等事宜。 ...

Story Protocol is an L1 blockchain aiming to revolutionize intellectual property.In today’s video, we break down what @StoryProtocol is, how it works, and what’s next on its roadmap.Watch the full video 👉 https://t.co/bhVbQwPzWE https://t.co/ehe8J8mUVP ...

Netflix seems to have accidentally hit it right. What's going on here. Why does nobody know nothing right now.Only about 12% of Americans now go to the movies at least once a month and about a quarter of Americans don't go to the movies at all. So movie going is going down. Movie studios rely on old names that we all know, which means that a movie like K-pop Demon Hunters, they don't know what to do with it because it's new and they're afraid to take that chance and put it in theaters.What are people in ent ...

Overcoming Adversity & Building Resilience - The speaker's story highlights the power of resilience and a "never give up" attitude in overcoming societal expectations and personal challenges [2][3][7] - Early experiences of being underestimated and rejected fueled the speaker's determination to succeed [1][9] - Seeking help and support from others is a crucial tool for overcoming obstacles [12] Entrepreneurial Journey & Business Strategy - The speaker started an entrepreneurial journey in 2013, facing rejection and underestimation but driven by a grit to win [9] - The company initially focused on underserved areas within intellectual property, specifically startups, universities, and memes [14] - The company chose to build a legacy business rather than a short-term venture [14] - The company grew from zero to over 300 team members [14] Lessons Learned & Future Vision - Rejection should be seen as redirection, and individuals should focus on self-improvement rather than external judgment [17] - Resilience is more important than resources; building a network is crucial for success [17][18] - Individuals should compete with themselves, focusing on personal growth and future potential [18] - Fearlessness and boldness are key to creating a legacy [19]

Core Insights - Kadimastem has secured a patent in Hong Kong for its IsletRx technology, enhancing its global intellectual property (IP) portfolio, which already includes patents in Europe, the United States, and India [1][2][3] - The IsletRx platform aims to provide a scalable source of insulin-producing islet-like cells to address diabetes, a significant health challenge affecting millions globally [5][3] - The economic impact of diabetes in Hong Kong is substantial, with an estimated 706,000 adults affected, leading to lifetime healthcare costs averaging $125,000 per patient, translating to a potential economic burden of approximately $90 billion [3][4] Company Overview - Kadimastem Ltd. is a clinical-stage cell therapy company focused on developing allogeneic, "off-the-shelf" cell products for neurodegenerative diseases and diabetes [7] - NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company dedicated to innovative therapies for central nervous system disorders [6]